Brief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
22/09/2026 12:04
BRIEF-Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million Sept 22 (Reuters) - Ligand Pharmaceuticals Incorporated LGND.O:
LIGAND ACQUIRES ROYALTY AND MILESTONE INTEREST IN SANTEN’S RYJUNEA® FROM SYDNEXIS FOR $23 MILLION
LIGAND PHARMACEUTICALS INCORPORATED - TO RECEIVE TIERED ROYALTY ON RYJUNEA NET SALES IN EMEA
LIGAND PHARMACEUTICALS INCORPORATED - BUYS RIGHTS TO ROYALTY AND MILESTONE PAYMENTS ON RYJUNEA IN EMEA
LIGAND PHARMACEUTICALS INCORPORATED: ACQUIRED PAYMENT RIGHTS INCLUDE A TIERED LOW-DOUBLE-DIGIT TO HIGH-TEENS ROYALTY ON RYJUNEA NET SALES IN EMEA
Source text: ID:nGNX4sKMRw
Further company coverage: LGND.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan